Evidence map›Paper›PMID 26209062›Full record

ArticleMolecular and cellular biochemistry2015

Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity.

Carina T Scoparo, Glaucio Valdameri, Paulo R Worfel, Fernanda A L B Guterres, Glaucia R Martinez, Sheila M B Winnischofer, Attilio Di Pietro, Maria E M Rocha

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Dual modulation of intracellular CaJournal of molecular histology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Carina T ScoparoDepartment of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba-PR, Brazil.
Glaucio ValdameriDepartment of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba-PR, Brazil.
Paulo R WorfelDepartment of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba-PR, Brazil.
Fernanda A L B GuterresDepartment of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba-PR, Brazil.
Glaucia R MartinezDepartment of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba-PR, Brazil.
Sheila M B WinnischoferDepartment of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba-PR, Brazil.
Attilio Di PietroEquipe Labellisée Ligue 2014, BMSSI UMR 5086 CNRS, IBCP, Université Lyon 1, Lyon, France.
Maria E M RochaDepartment of Biochemistry and Molecular Biology, Federal University of Paraná, Curitiba-PR, Brazil. maelimerlin.rocha@gmail.com.
Universidade Federal do Paraná · BRStructural and Molecular Basis of Infectious Systems · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma is the third most common cause of cancer-related deaths worldwide. Furthermore, the existing pharmacological-based treatments are insufficiently effective and generate many side effects. Hispidulin (6-methoxy-5,7,4'-trihydroxyflavone) is a flavonoid found in various medicinal herbs that present antineoplastic properties. Here we evaluated how modulation of reactive oxygen species (ROS) and alterations of antioxidant defenses could be associated to the antiproliferative effects of hispidulin in HepG2 cells. In addition, we studied the inhibitory activity of hispidulin on the efflux of drugs mediated by ABC transporters involved in multidrug resistance. In order to understand the increase of intracellular ROS promoted by hispidulin, we investigated the mRNA expression levels and activities of antioxidant enzymes, and the GSH/GSSG ratio. We showed that hispidulin significantly down-regulated the transcription levels of catalase, leading to reduction of enzyme activity and decrease of the GSH content. We also observed that, in the presence of N-acetylcysteine or exogenous catalase, the proliferation was lowered back to the control levels. These data clearly indicate a strong involvement of intracellular ROS levels for triggering the antiproliferative effects. We also demonstrated that the inhibition produced by hispidulin on drug efflux was specific for ABCG2, since no effects were observed with ABCB1 and ABCC1. Furthermore, HepG2 cells were more sensitive to hispidulin-mediated cell death than immortalized L929 fibroblasts, suggesting a differential toxicity of this compound between tumor and non-tumor cell lines. Our results suggest that hispidulin constitutes a promising candidate to sensitize chemoresistant cancer cells overexpressing ABCG2.

Indexed as

AnimalsAntioxidantsApoptosisATP-Binding Cassette, Sub-Family C ProteinsATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2Biological TransportCarcinoma, HepatocellularCatalaseCell Line, TumorCell ProliferationCell SurvivalFlavonesGlutathioneHEK293 CellsHep G2 CellsAbcg2 protein, mouseAntioxidantsATP-Binding Cassette, Sub-Family C ProteinsATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2CatalaseFlavonesGlutathionehispidulinMitoxantronemultidrug resistance-associated protein 1Reactive Oxygen SpeciesRNA, MessengerABCG2CatalaseHepG2 cellsHispidulinROS

Identifiers

PMID26209062
OpenAlexW946895768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.